

## References

### I-168

1. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous nonsmall-cell lung cancer (SQUIRE): an open-label, randomized, controlled phase 3 trial. *Lancet Oncol.* 2015;763–74.
2. Paz-Ares L, Mezger J, Cluleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as firstline therapy in patients with stage IV non-squamous non-small cell lung cancer (INSPIRE): an open-label, randomized, controlled phase 3 study. *Lancet Oncol.* 2015;328–337.
3. MICROMEDEX®SOLUTIONS Compendia. 2020. Necitumumab.
4. Clinical Pharmacology Compendia. [database online]. 2020. Tampa FL: Gold Standard, Inc. Necitumumab.
5. PORTRAZZA (necitumumab) [package insert]. Indianapolis, IN. Eli Lilly and Company: 2015. Revised 11/2015.
6. Ciuleanu T, Socinski M, Obasaju C, et. al. Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous NonSmall-Cell Lung Cancer. *Clin Lung Canc.* 2018;19(2):130-138
7. Genova C, Socinski M, Hosak R, et. al. EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. *J Thorac Oncol.* 2018;13(2);228-236.
8. Genova C, Hirsch FR. Clinical potential of necitumumab in non-small cell lung carcinoma. *OncoTargets & Therapy.* 2016;9:5427-5437.
9. Spigel DR, Luft A, Depenbrock H, et al. An Open-label, randomized, controlled phase II study of paclitaxel-carboplatin chemotherapy with necitumumab versus paclitaxel-carboplatin alone in first-line treatment of patients with stage IV squamous non-small-cell lung cancer. *Clinical Lung Cancer.* 2017;18(5):480-488.